Toxicity and Behandeling Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapie in Patiënten met High-Risico Locally Gevorderd Rectal Cancer: A Secondary Outcome Analyse of the MEND-IT Trial
Total neoadjuvant therapy (TNT) is a promising strategy to improve tumor response and oncological uitkomsten in patiënten met locally advanced rectal cancer (LARC) , particularly in those with high-risk tumor characteristics.
Abstract (original)
Total neoadjuvant therapy (TNT) is a promising strategy to improve tumor response and oncological outcomes in patients with locally advanced rectal cancer (LARC) , particularly in those with high-risk tumor characteristics. Although triplet chemotherapy (ie, FOLFOXIRI) is currently used exclusively for metastatic disease, it may offer benefits in the curative treatment of high-risk LARC by enhancing tumor response and reducing the risk of distant metastases. However, its broader use is limited by concerns regarding toxicity.
Dit artikel is een samenvatting van een publicatie in Int J Radiation Oncology. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.
Lees het volledige artikelDOI: 10.1016/j.ijrobp.2025.12.052